Nurix therapeutics presents positive clinical results from its novel btk degrader (nx-2127) at the 64th american society of hematology (ash) annual meeting

Treatment with nx-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (cll) patients regardless of bruton's tyrosine kinase (btk) mutational status
NRIX Ratings Summary
NRIX Quant Ranking